Therefore, the anti-inflammatory SIRT1/HMGB1 pathway may act as a typical pharmacological target to attenuate the progression of NAFLD for the development of new drugs. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.